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Antimicrobial Susceptibil it ies of Aerobic Isolates from Respiratory
Samples of Young New Zealand Horses
L.J. Toombs-Ruane, C.B. Riley, A.T. Kendall, C.F. Bolwell, J. Benschop, and S.M. Rosanowski
Background: Decreased efficacy of antimicrobials and increased prevalence of multidrug resistance (MDR) is of concern
worldwide.
Objectives: To describe and analyze bacterial culture and antimicrobial susceptibilities from respiratory samples submitted
from young horses (4 weeks to 3 years old).
Animals: Samples from 289 horses were submitted to a commercial laboratory.
Methods: A retrospective database search of submissions made to a New Zealand veterinary laboratory between April
2004 and July 2014. The results of in vitro susceptibility testing by Kirby-Bauer disc diffusion were described and tabulated
for the major bacterial species isolated. Multiple correspondence analysis (MCA) was used to describe the clustering of MDR
isolates and selected demographic variables.
Results: Overall, 774 bacterial isolates were cultured from 237 horses, the majority of these isolates were gram-positive
(67.6%; 95% CI 64.3–70.9%). Streptococcus spp. were the most common genus of bacteria isolated and were 40.1% (95%
CI 36.6–43.5%) of the isolates cultured. Susceptibility of Streptococcus spp. to penicillin, gentamicin, and ceftiofur was
>85%. Overall, gram-negative susceptibility to ceftiofur, tetracycline, and TMPS was <75%. MDR was defined as resistance
to 3 or more antimicrobials, and was found in 39.2% of horses (93/237; 95% CI 33.0–45.5%).
Conclusions and clinical importance: Culture and susceptibility results have highlighted that MDR is an emerging problem
for young horses in New Zealand (NZ), where a bacterial respiratory infection is suspected. This should be considered when
prescribing antimicrobials, and emphasizes the need for submission of samples for culture and susceptibility.
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There has been an increased attention placed uponantimicrobial resistance (AMR) in the medical1 and
veterinary2 professions. Veterinary use of antimicrobials
in horses has recently come under greater scrutiny, with
the use of antimicrobials in respiratory disease identified
as an area where inappropriate treatment occurs with a
relatively high frequency.3,4 In a survey using clinical case
scenarios, 67.4% (763/1128) of UK veterinarians sur-
veyed indicated that they would prescribe a trimetho-
prim-sulfonamide (TMPS) combination to a coughing
pyretic yearling, whereas 10.4% would prescribe peni-
cillin, 2.9% oxytetracycline, and 5.8% a 3rd or 4th gener-
ation cephalosporin.3 These practices describe
antimicrobial treatments that might not be effective,3 and
have the potential to increase the risk of AMR develop-
ment and carriage.5,6 The prescription practices of New
Zealand (NZ) equine veterinarians are not known.
Respiratory disease is a source of economic loss,
especially for young performance horses.7 This is not
only confined to known contagious pathogens such as
Rhodococcus equi, Streptococcus equi subspecies equi,
Streptococcus equi subspecies zooepidemicus, or equine
herpes virus (EHV), but includes losses associated with
inflammatory respiratory disease.8–10 It is essential that
bacterial respiratory infections are correctly identified
and diagnosed,4,10 because laboratory results should be
used in conjunction with the clinical picture to justify
the clinical use of antimicrobials.11
It is also important to have an understanding of the
susceptibility of bacterial pathogens at a regional level,
to underpin the development of regionally relevant
guidelines for the prudent use of antimicrobials.11–13
This study aimed to examine the patterns of antimicro-
bial susceptibility of bacterial isolates from young NZ
horses with respiratory disease. The overarching objec-
tive of this work is to help provide a rationale for selec-
tion of appropriate antimicrobial treatment for
suspected or confirmed bacterial respiratory disease.
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Materials and methods
Data collection
Records of antimicrobial susceptibilities (in vitro) of bacterial
isolates cultured from equine samples submitted to New Zealand
Veterinary Pathology (NZVP© Ltd, Auckland, Hamilton and
Palmerston North laboratories, NZ) between April 2004 and July
2014 were assessed. All equine culture and susceptibility records
submitted to the laboratory between the study dates were available
for selection. Unique accession numbers were used to identify sam-
ples, and each accession number was assumed to be from different
animals. Clinical case histories were not available in the database,
so samples submitted from the same horse on different occasions
were not able to be identified.
Case selection
The susceptibilities of the bacterial isolates from equids were
selected from horses between 4-weeks of age and 3-years old as
defined by and listed in the NZVP database. Three age categories
were defined according to the definitions used by the laboratory
submission forms, with the age group of 1–23 months collapsed to
include submissions listed as “weaner (weaning)” and “yearling”
age categories, 2-year olds and 3-year olds.
Only samples described as likely respiratory (ie, “bronchoalveo-
lar lavage,” “lung,” “lung swab,” “lymph node swab,” “nasal dis-
charge,” “nasal swab,” “pharyngeal swab,” “pleural fluid,”
“respiratory swab,” “sinus,” “sinus swab,” “throat swab,” “thoracic
fluid,” “tracheal swab,” and “tracheal wash”) were included for
analyses. Lymph node samples were included because of the absces-
sation of respiratory-associated lymph nodes with Streptococcus
equi subspecies equi infection (strangles or metastatic strangles).14
Horses with more than 1 sample submitted were evaluated for
similarity of bacterial culture, and exclusion of an isolate was
made if two bacterial isolates cultured from the same horse had an
identical antibiogram. The exclusion of apparently identical bacte-
ria (from the same horse) resulted in one sample per horse
assessed. For the purposes of comparing demographic informa-
tion, only one sample per horse (if only negative culture results
were obtained) was included in the dataset for analysis.
Culture and susceptibility, identification and
classification
The laboratory selection of antimicrobials for testing was based
either on standardized NZVP protocols, individual microbiologist
selection, or submitting clinician request. Aerobic culture results
were selected for analysis; anaerobic and fungal isolates were not
assessed. Disc-diffusion tests of the cultured isolates were based on
a standardized protocol,15 and the definition of susceptibility was
based on the Clinical Laboratory Standards Institute (CLSI) recom-
mendations for antimicrobial/bacterial isolate combinations.16,17
The antimicrobials examined included ceftiofur, enrofloxacin,
gentamicin, penicillin, tetracycline, and TMPS. Multidrug resistance
was defined as an isolate being resistant to three or more of the fol-
lowing antimicrobials:18 ceftiofur, enrofloxacin, gentamicin, peni-
cillin, tetracycline, and TMPS. One E. coli isolate was removed from
the dataset before analyses attributable to the results of testing with
three of these antimicrobials not being available.
Data analysis
Data were stored and manipulated in Microsoft Excel and
Microsoft Access.a Demographic and signalment variables
included region of origin, age, and breed. The anatomic origin (if
known) and type of submitted sample was tabulated. The data for
bacterial isolates described in the records were then examined with
respect to susceptibility to antimicrobials and demographic factors,
in particular age and region. Data were described by using counts,
percentages, and 95% confidence intervals (CI). Pearson’s chi-
squared or Fisher’s exact tests were performed on isolates with
respect to the MDR status and selected submission factors to deter-
mine p-values for significant associations. Multiple correspondence
analysis (MCA)19 was performed to visualize multidrug resistance
on a two-dimensional plot. Multiple correspondence analysis is a
unique way to describe ordinal and categorical data, as it allows for
the visualization of associations between multiple variables.19 In this
study, MCA was used to visually describe demographic factor vari-
ables, and the way these variables were related to the MDR status.
A two-dimensional plot was generated from a matrix of bacterial
isolate data (including MDR status). Variables clustering about the
center of the plot are considered average for the data set.19
For each bacterial isolate, the demographic factors of “region,”
“age,” and “date” were included, as was the MDR status. The
MDR status was assessed at the isolate level. The dates were
recorded into 2 time span categories: April 2004–2008 (inclusive),
and July 2009–2014 (inclusive). These time spans were chosen
based on the total number of submissions per year, so that within
each group the years were relatively similar. The analysis was
adjusted to account for the inflation of the Burt Matrix using the
joint method.19 All statistical analyses were conducted in using
STATA version 13.1 software.b
Results
Over the 10-year study period, records were available
for 289 horses from which respiratory samples were
submitted for culture. Aerobic bacteria were cultured
from 237 (82.0%) of these submissions, antimicrobial
susceptibilities were recorded, and demographic infor-
mation summarized (Table 1).
Samples
Samples for which susceptibilities were not recorded
included those from which an anaerobic bacterium or
fungus was cultured (without also culturing aerobic bac-
teria), those that yielded mixed bacterial growth were
not subsequently speciated and susceptibility tested, and
those for which selective culture for Rhodococcus equi
and Streptococcus equi subspecies equi were negative. In
total, 52/289 (18.0%; 95% CI 13.6–22.4%) of the respi-
ratory samples submitted from horses were not culture-
positive (ie, had no susceptibilities to antimicrobials
recorded); 6/52 (15.4%; 95% CI 5.6–25.2%) had two
submitted samples that were both culture-negative. Of
the samples resulting in a positive culture, 119/237
(50.2%; 95% CI 43.8–56.6%) were from nasal swabs
and tracheal samples (“swab” or “wash”) accounted for
98/237 (41.4%; 95% CI 35.1–47.6%) of the samples. A
single bacterial species was cultured from 26/237
(11.0%; 95% CI 7.0–14.9%) submissions; 2 to 4 bacte-
rial species were cultured from 175/237 (73.8%; 95% CI
68.2–79.4%); 5-to-7 bacterial species were cultured from
36/237 (15.2%; 95% CI 10.6–19.8%) of submissions;
and 1/237 (0.4%; 95% CI 0.4 to 1.2%) had 11
bacterial species isolated that were tested for antimicro-
bial susceptibilities.
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Bacterial culture
A total of 774 unique bacterial isolates were cultured
from 237 horses with positive growth from the submitted
samples. Of these isolates, 523/774 (67.6%; 95% CI 64.3–
70.9%) were gram-positive; Staphylococcus spp. accounted
for 119/523 (22.8%; 95% CI 19.2–26.3%) of these isolates,
of which 65/119 (54.6%; 95% CI 45.7–63.6%) were Sta-
phylococcus aureus. Streptococcus spp. constituted 310/523
(59.3%; 95% CI 55.1–63.5%) of all gram-positive isolates.
Of these 125/310 (40.3%; 95% CI 34.9–45.8%) were iden-
tified as Streptococcus equi subspecies zooepidemicus. Ente-
rococcus spp. accounted for 18/523 (1.6%; 95% CI 1.9–
5.0%) of cultured isolates. Gram-negative bacterial iso-
lates accounted for 251/774 (32.4%; 95% CI 29.1–35.7%)
of the isolates. Enterobacteriaceae constituted 164/251
(65.3%; 95%CI 59.5–71.2%) of all gram-negative isolates.
Of these 61/164 (37.2%; 95% CI 29.8–44.6%) were identi-
fied as Escherichia coli. Pseudomonas spp. accounted for
32/251 (4.1%; 95% CI 8.6–16.9%) of gram-negative iso-
lates, and Actinobacillus spp. and Pasturella spp.
accounted for 9/251 (2.3%; 95% CI 1.3–5.9%), and 2/251
(1.1%; 95% CI 0.3 to 1.9%), respectively.
Antimicrobial susceptibility
Susceptibility results are described in Table 2. Antimi-
crobial susceptibility of gram-positive isolates were
<75% for tetracycline and TMPS, and >90% for gentam-
icin alone. Streptococcus spp. susceptibility to penicillin
was >97%. The lowest overall susceptibility found for a
gram-negative bacterium was to ceftiofur (55.6%). Mul-
tidrug resistance was recorded among the 773 eligible iso-
lates. Of these, 120/773 (15.5%; 95% CI 13.0–18.1%)
were resistant to 3 or more antimicrobials. Multidrug-re-
sistant isolates were cultured from 93/237 (39.2%; 95%
CI 33.0–45.5%) horses (range 1–4 MDR isolates per
horse). Of all gram-positive isolates, 55/523 were MDR
(10.5%; 95% CI 7.9–13.1%). Within a specific genera of
gram-positive isolates, Enterococcus spp. included 3/18
MDR isolates (16.7%; 0–33.9%), Staphylococcus spp.
12/119 MDR isolates (10.1%; 95% CI 4.7–15.5%), and
Streptococcus spp. 12/310 MDR isolates (3.9%; 95% CI
1.7–6.0%). Overall 65/250 (26.0%; 95% CI 20.6–31.4%)
gram-negative bacteria cultured were MDR. In the fam-
ily Enterobacteriaceae there were 39/163 MDR isolates
cultured (23.9%; 95% CI 17.4–30.5%).
Statistical analyses
The age of horse (P = .05, Pearson’s v2 test) and date
of submission (P = .003, Pearson’s v2 test) were shown
to have a significant association with MDR status.
Region (P = .60 Fisher’s exact test), sex (P = .40, Pear-
son’s v2 test), and breed (P = .21, Fisher’s exact test)
Demographic
Groups
Culture
Positive
n
Total
Submissions
n
Proportion
Positive
% (95% CI)
Region Auckland 61 70 87.1 (79.2–95.0)
Waikato 135 166 81.3 (75.4–87.2)
North Island (other) 29 37 78.4 (65.1–91.6)
South Island (other) 12 16 75.0 (53.8–96.2)
Year 2004 6 6 100
2005 8 8 100
2006 8 8 100
2007 13 13 100
2008 18 19 94.7 (84.6–104.8)
2009 33 46 71.7 (58.7–84.7)
2010 25 45 55.6 (41.1–70.1)
2011 34 38 89.5 (79.8–99.2)
2012 26 26 100
2013 50 56 89.3 (81.2–97.4)
2014 16 24 66.7 (47.8–85.6)
Age 1–23 months 129 162 79.6 (73.4–85.8)
2 years 56 67 83.6 (74.7–92.5)
3 years 52 60 86.7 (78.1–95.3)
Breed Standardbred 19 22 86.4 (72.0–100.7)
Thoroughbred 172 216 79.6 (74.3–85.0)
Other breed 13 16 81.3 (62.1–100.4)
Unknown 33 35 94.3 (86.6–102.0)
Sex Female 97 115 84.3 (77.7–91.0)
Male 113 131 86.6 (80.4–92.2)
Unknown 27 43 62.8 (48.3–77.2)
All Submissions Total 237 289 82.0 (77.6–86.4)
Region “South Island (other)” includes all regions in the South Island; Region “North
Island (other)” includes Bay of Plenty, Manawatu–Wanganui, Northland, Wellington; 2014
is January–July 2014. Proportion positive indicates Culture positive/Total submissions, as a
percent.
Table 1. Demographic submission
information from 289 horses from
which respiratory samples for cul-
ture and susceptibility were submit-
ted to a New Zealand laboratory
(2004–2014).
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were not significantly associated with the occurrence of
MDR in this dataset.
Multiple correspondence analysis
Figure 1 shows the results of multiple correspon-
dence analysis, which was used to graphically depict
associations between selected demographic factors and
MDR. The plot shows that non-MDR isolates (“No”)
lie close to the center, and this represents the most
common (or average) result, indicating that most iso-
lates were not MDR. Also shown in the plot is a clus-
tering of 2-year-olds, submission years 2009–2014, and
the Waikato region of NZ with MDR isolates (“Yes”).
In total, 95% of the variance is explained in 2 dimen-
sions, with most of the variance shown in dimension 1.
Variables contributing most to the variation in the
analysis were date (dimension 1) and geographic region
(dimension 2).
Discussion
Based on respiratory sample culture and susceptibility
results from 2004 until 2014, in vitro resistance was
found to the antimicrobials that are used for the treat-
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Fig 1. Multiple correspondence analysis (MCA) in 2 dimensions,
using a joint method, of 773 bacterial isolates cultured from NZ
horses 2004–2014. Dimension 2 is shown on the y-axis, dimension
1 on the x-axis. For interpretation, the dimension that a variable
contributes to can be visually assessed, for example year (‘04–’08;
‘09–14) is shown as different by the spread of the variables on the
x-axis (dimension 1). Age = age of horse (variables are 4 weeks to
23 months; 2 years; 3 years) associated with each bacterial isolate;
MDR = multidrug resistant to ≥3 antimicrobials (variables are
yes; no); Region = region of origin of the bacterial isolates (vari-
ables are Auck = Auckland; Other (North I.) = North Island
(Other); Other (South I.) = South Island (Other);
Waik = Waikato); Time period = year of submission (grouped)
(variables are ’04–’08 = 2004–2008; ’09–’14 = 2009–2014 .
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ment of respiratory infections in young NZ horses.
Treatments such as TMPS were not effective in vitro
against bacterial respiratory pathogens in many cases.
However, penicillin, gentamicin, and ceftiofur were
effective in vitro against multiple species of gram-posi-
tive bacteria in most cases, with gentamicin and enro-
floxacin commonly found to be effective in vitro against
gram-negative bacteria.
Streptococcus spp. accounted for a high proportion
of all isolates cultured, suggesting that streptococcal
infections are more common than other causes of bacte-
rial respiratory infection (or colonization) in NZ. In a
study of British National hunt racehorses, Streptococcus
spp. (nonhemolytic and Viridans group), Staphylococcus
spp., Bacillus spp., and Actinobacillus/Pasteurella spp.
in descending frequency of occurrence were most
commonly isolated from the respiratory tract.20 These
bacteria have a known or potentially causal role in
equine respiratory disease.3 In contrast, Actinobacillus
and Pasteurella were not cultured in high proportions
in this study. These differences could reflect the diagnos-
tic practices of veterinarians in NZ, and further investi-
gation into this is warranted. As nothing was known
regarding previous treatment with antimicrobials or
clinical history of horses from which samples were sub-
mitted to NZVP laboratories, results presented in this
study should be interpreted with caution.
Ceftiofur has been recommended for the treatment of
respiratory streptococcal infections in horses.21
However, the results of this study do not support a
therapeutic advantage over the use of penicillin. Strep-
tococcus spp. are generally susceptible to penicillin,22,23
and there was little appreciable difference between peni-
cillin and ceftiofur in vitro susceptibility in this study
(ceftiofur 95.1–98.9% versus penicillin 95.2–99.0%). In
addition, it has been recommended that ceftiofur, a 3rd
generation cephalosporin, and enrofloxacin should not
be used as first-line treatments as they have been identi-
fied as critically important antimicrobials by the World
Health Organization.13
Overall, the in vitro susceptibility of bacteria to
TMPS was low for both gram-positive and gram-nega-
tive isolates. Staphylococcal isolates were susceptible to
TMPS (82.4%); however, their association with clinical
respiratory infections is not as common and that of
Streptococcal species.20 Staphylococcus spp. are more
likely to be associated with contamination from the
upper respiratory tract.24,25 In NZ, TMPS is one of the
few antimicrobials that is available in an oral formula-
tion and accounts for a high proportion of antibiotic
sales26 and based upon a recent survey, its misuse on-
farm is suspected.27
In a recent retrospective study of diagnostic samples
of beta-hemolytic Streptococcus submitted to a US lab-
oratory over a 10-year period, a statistically significant
increase in resistance of Streptococcus equisimilis to
both gentamicin and tetracycline was noted.23 In the
current study, the overall susceptibility of Streptococcus
spp. to gentamicin was 88.5–94.7% (95% CI), and over-
laps with the susceptibility reported in the US study of
between 83.3% and 91.2%.23 It is possible that this sim-
ilarity is coincidental, and reflects the classification of
bacteria, as there is intrinsic variation in the susceptibil-
ities to antimicrobials that different species of Strepto-
coccus exhibit.22 However, gentamicin is not an
appropriate first choice for the treatment of respiratory
infections in horses, despite bacteria cultured in this
study having overall high susceptibility to the antimi-
crobial, as it is does not appear to reach therapeutic
concentrations in respiratory secretions.28,29 However,
in the presence of inflammation and increased blood
flow, systemic administration of gentamicin is likely to
penetrate affected lung tissue and have chemotherapeu-
tic effects.30,31
Bacteria that were resistant to 3 or more antimicro-
bials appeared to be relatively common in the study
population, with at least one MDR isolate cultured
from 39.2% of horses. The age of the horse and the
year of submission were both significantly associated
with MDR status and this was reflected in the MCA
plot. Multiple correspondence analysis is a method not
commonly reported in veterinary research, although it
has been effectively utilized to describe focal bone min-
eral density patterns.32 Based on the number of different
variables potentially associated with MDR, it was used
here to assess multiple factors for associations, without
assessment of statistical significance. In this dataset,
there was a clustering of isolates from the geographic
region of Waikato, with 2-year-old horses and in the
submission years 2009–2014. This is an indication that
submission of MDR isolates was common in this age
group of animals, and these could be potential risk fac-
tors for MDR carriage and infection. Although there
might be a geographical association between veterinar-
ian submission patterns and the results of this study,
veterinarian involvement on NZ farms is varied,27 and
conclusions cannot be made based upon these results.
Further investigation of this is warranted from both a
treatment and public health perspective.18
The overuse and misuse of antimicrobials in equine
medicine has been described in Canada and the United
Kingdom, especially in the treatment of respiratory con-
ditions.3,4 There was no knowledge of pretreatment or
overuse of antimicrobials in the animals from which
samples were taken for this study, although increased
antimicrobial resistance among host bacteria after the
use of antimicrobials has been described in other equine
populations.6,33 This might have been a contributing
factor to the high proportion of horses culturing an
MDR isolate, but confirmatory data were not available
in this retrospective record-based study.
Some of the limitations of this study are inherent
with using retrospective data from disc-diffusion suscep-
tibility testing. Results of disc-diffusion testing, even
where standards are used,16 are subject to changes in
the definition of susceptibility by the standards (eg,
CLSI). This contrasts with studies where MIC data are
used,34 and antimicrobial concentrations are stated for
a given susceptibility breakpoint, and thus could
improve the quality of retrospective temporal analysis.
Another limitation of using data from commercial labo-
ratories includes the inability to relate antimicrobial sus-
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ceptibilities to an accurate and well described case his-
tory.11
It should also be noted that the isolates included in
this study were submitted to one of two commercial
diagnostic microbiology laboratories in NZ, and there-
fore not necessarily representative of the broader popu-
lation. In addition, a likely bias exists from the origin
of samples, with a majority of samples submitted from
the Waikato region of NZ (57.4%). This bias reflects
the location of the greatest concentration of horses in
the commercial Thoroughbred population in NZ.35,36
The laboratories from which the data were obtained are
situated in the North Island of NZ, and although a
small proportion of samples originated from the South
Island (Table 1), any true regional differences in antimi-
crobial susceptibility were not able to be accurately
described. Breed variations are likely to be emphasized
by this same regional bias, as well as the economic util-
ity of racehorse breeds in the age range chosen for this
study. Data from respiratory samples were likely lost
from this study because of incomplete information
regarding the source of samples, information that was
not completed by the submitting veterinarian or clinic.
Although an attempt was made to describe one sample
per horse, the potential inclusion of samples from the
same horse on multiple occasions is a limitation in this
study and has a potential to bias the results by the
inclusion of potentially more resistant isolates. As there
was no evidence of association between “unknown”
submission information and the culture of MDR iso-
lates, it is possible that the missing susceptibility data
would not have been from the MDR isolates. Provi-
sions of clinical history, especially previous treatment,
as well as signalment information are important not
only so the laboratory can provide comprehensive feed-
back, but also to allow for the continued monitoring of
antimicrobial susceptibility patterns.37
The samples in this study came predominantly from
nasal (50.2%) and tracheal (41.4%) samples, and
although respiratory disease is typically stratified into
“upper” and “lower” airway disease, the exact mode of
collection of the samples used in this study was not
specified. The implication is that even if a sample has
been labeled as tracheal, bronchial, or lung, there is a
significant likelihood of contamination from the upper
airway flora to occur.20 Bacterial isolates from all sam-
ple sources were described together, as the potential
clinical implications to keeping them separate are lost in
the limitations of the study methodology. Even a strin-
gent laboratory protocol is also subject to variations
year-to-year and between laboratories; there are inher-
ent limitations to any retrospective study of antimicro-
bial susceptibility or resistance.38 Nevertheless the
authors suggest that the data described here provide a
valuable and necessary contribution to understanding of
general clinical antimicrobial susceptibility and
resistance in NZ.
The results of this study confirm that penicillin is an
appropriate first-line antimicrobial for use in most
horses in NZ where a streptococcal respiratory infection
is suspected, when results of the samples submitted for
bacterial culture and susceptibility are pending. A sus-
pected decrease of in vitro bacterial susceptibility to
commercially available veterinary antimicrobials
(including MDR) is of concern, and culture and
susceptibility should be included in the appropriate
diagnosis of bacterial disease. Ongoing monitoring of
culture and susceptibility results at a local level should
be performed to ensure guidelines reflect regional
antimicrobial susceptibilities, and therefore inform
appropriate antimicrobial selection in the future. The
continued monitoring and surveillance of antimicrobial
susceptibility and resistance in NZ is warranted.
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